View PowerPoint Presentation - Vision Research Coordinating Center

More documents

Recommendations

Info

Percent of Medication Patients on Different MedicationsPatients may be on more than one medicationEpinephrine/Dipivefrin100.00%90.00%80.00%Parasympathetic agentAlpha-2 adrenergic agonistTopical CAIProstaglandin AnalogBeta-adrenergic antagonist70.00%60.00%50.00%40.00%30.00%20.00%10.00%June, 20020.00%0122436Months48607284
Progress and Outcome of Study ParticipantsMedication Observation Alln % n % n %Randomized 817 100 819 100 1636 100Died 26 3.2 29 3.5 55 3.4Inactive 89 10.9 84 10.2 173 10.6Non-adherence torandomizationReproducible VF or Optic Discabnormality due to any cause40 4.9 42 5.1 82 5.081 9.9 137 16.7 218 13.3Endpoints attributed to POAG 36 4.4 89 10.9 125 7.6Log rank p
Page 1 and 2: The Ocular HypertensionTreatment St
Page 3 and 4: Why did we do this study?Don’t we
Page 5 and 6: Ocular Hypertension Treatment Study
Page 7 and 8: Patient found eligible for OHTS•
Page 9 and 10: Baseline Characteristics by Randomi
Page 15: IOP By RaceMedicationObservationAfr
Page 19 and 20: Proportion POAG1 st Visual Field PO
Page 21 and 22: First POAG Endpoint per Participant
Page 23 and 24: Treatment perhaps less protectivein
Page 25 and 26: Percent Reporting Changes inIris, L
Page 27 and 28: Borderline Safety DifferencesBetwee
Page 29 and 30: Significant Baseline Predictive Fac
Page 31 and 32: Significant Baseline Predictive Fac
Page 33 and 34: POAG Endpoints by Central Corneal T
Page 35 and 36: 60-year-old WF IOP 24 / 24 C/D rati
Page 37 and 38: 60-year-old WF IOP 28 / 28 C/D rati
Page 39 and 40: 72-year-old BM IOP 25 / 25 C/D rati
Page 41 and 42: Weaknesses1. Convenience sample rat
Page 43 and 44: Possible Misinterpretations of OHTS
Page 45: OHTS Clinical CentersBascom Palmer

View PowerPoint Presentation - Vision Research Coordinating Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?